Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

The National Medical Products Administration has officially approved BBM-H901 (Dalnacogene Ponparvovec Injection) for the treatment ... B gene therapy drug and the first recombinant adeno-associated ...

Researchers at Children's Hospital of Philadelphia (CHOP) in collaboration with researchers at Royal Prince Alfred Hospital in Sydney, Australia announced the results of the longest follow-up study to ...

Belief BioMed and Takeda China today jointly announced that BBM-H901, has been officially approved by the National Medical ...

The National Medical Products Administration has officially approved BBM-H901 (Dalnacogene Ponparvovec Injection ... and the first recombinant adeno-associated virus (rAAV) vector gene therapy ...

BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time to buy.

The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A ... and ROCTAVIAN, an adeno associated virus vector for the ...

The gene therapy BBM-H901 (dalnacogene ponparvovec) has been approved in China for adults with moderate to severe hemophilia ...

Administered via a once weekly subcutaneous injection, Hympavzi is approved ... to cells in the liver with the help of a harmless adeno-associated virus called AAV5. It’s administered via a single ...